CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CTMX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/23	05 : 05	GlobeNewswire Inc.	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/17	05 : 15	GlobeNewswire Inc.	CytomX Therapeutics Announces New Employment Inducement Grants	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/14	05 : 00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05 : 41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05 : 10	GlobeNewswire Inc.	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05 : 10	GlobeNewswire Inc.	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/08	05 : 15	GlobeNewswire Inc.	CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/01	21 : 00	GlobeNewswire Inc.	CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/04/08	21 : 00	GlobeNewswire Inc.	CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/04/03	21 : 00	GlobeNewswire Inc.	CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/21	21 : 00	GlobeNewswire Inc.	CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/18	21 : 00	GlobeNewswire Inc.	CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05 : 30	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05 : 10	GlobeNewswire Inc.	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05 : 00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/11	19 : 39	IH Market News	U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/04	22 : 00	GlobeNewswire Inc.	CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/02/27	22 : 00	GlobeNewswire Inc.	CytomX Therapeutics to Present at Upcoming March Investor Conferences	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/24	22 : 00	GlobeNewswire Inc.	CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/20	10 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/20	10 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc